Gabriele Fischetto

Gabriele joined Johnson & Johnson almost 20 years ago and during this time has held various positions across Johnson & Johnson Medical Devices in country and regional positions.

In his current role, Gabriele leads several companies within the Medical Devices sector across Europe, the Middle East and Africa, including Biosense Webster. A global leader in the science of diagnosing and treating heart rhythm disorders. Biosense Webster partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide, towards their mission of curing atrial fibrillation.

Gabriele has a life-long passion for the role medical devices plays in helping people to live healthy lives and graduated as Electronic Engineer at the University of Bologna, where he resides today with his family.

In 2019, and in every corner of the world, pressing issues affect patients and their way of life. Consequently, this impacts upon their loved ones and personal, professional and social communities. There are conditions and diseases that receive a lot of attention and are broadly recognised and there are those that don’t. Atrial fibrillation (AF,) unfortunately, falls into the latter category and although it is the most common heart arrhythmia – affecting one in four of us over 40 years of age – there is a general misconception about AF amongst the general public. In fact, 45% of people incorrectly believing that AF is not a life-threatening condition. Our recent report, The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe , aims to renew focus on this health topic and to protect more lives from this growing disease. AF is an irregular and, often, fast heart rhythm that results in the uncoordinated contraction of the top two chambers of the heart. This can cause blood clots leading patients to suffer AF-related strokes. AF sufferers are five times more likely to experience heart failure, 2.4 times more likely to experience a stroke and twice as likely to die from cardiovascular disease. What worries me is that AF is one of the world’s most understated significant health issues. Estimates suggest that AF is responsible for up to 2.6% of total annual healthcare expenditure in European countries. Eleven million people across Europe are suffering from AF, with the disease being almost as common as stroke and cancer. Ageing will lead to more cases of AF. We believe that there needs to be greater awareness of AF and more done to detect the disease earlier in patients. This would potentially reduce the chance of complications and the burden...